Cells must make appropriate fate decisions within a complex and dynamic environment 1 . In vitro studies indicate that the cytoskeleton acts as an integrative platform for this environmental input 2 . External signals regulate cytoskeletal dynamics and the cytoskeleton reciprocally modulates signal transduction 3,4 . However, in vivo studies linking cytoskeleton/signalling interactions to embryonic cell fate specification remain limited 5-7 . Here we show that the cytoskeleton modulates heart progenitor cell fate. Our studies focus on differential induction of heart fate in the basal chordate Ciona intestinalis. We have found that differential induction does not simply reflect differential exposure to the inductive signal. Instead, pre-cardiac cells employ polarized, invasive protrusions to localize their response to an ungraded signal. Through targeted manipulation of the cytoskeletal regulator CDC42, we are able to depolarize protrusive activity and generate uniform heart progenitor fate specification. Furthermore, we are able to restore differential induction by repolarizing protrusive activity. These findings illustrate how bi-directional interactions between intercellular signalling and the cytoskeleton can influence embryonic development. In particular, these studies highlight the potential for dynamic cytoskeletal changes to refine cell fate specification in response to crude signal gradients.
A core set of inductive signals guide multiple embryonic cell fate decisions. For example, fibroblast growth factor (FGF) signalling impacts the fate of heart, liver, brain and numerous other progenitor lineages 8, 9 . FGF and other inductive cues must be processed with high fidelity, as alterations in progenitor numbers can disrupt organ size and function 10 . However, labile embryonic cell interactions generate a high degree of signalling noise 1 . In vitro studies indicate that the cytoskeleton helps refine the response of cells to fluctuating micro-environments 2 . Although evidence is accumulating for similar processes in vivo, potential cytoskeletal contributions to FGF signalling or heart progenitor specification have not been investigated.
Low cell numbers, fixed lineages and rapid development make Ciona embryos a powerful model for in vivo analysis of cell signalling and fate specification [11] [12] [13] . The Ciona heart lineage can be traced back to four pre-cardiac 'founder' cells in the gastrulating embryo (two symmetrical pairs, each consisting of a B8.9 and B8.10 blastomere; Fig. 1a ). During neurulation (stage 15) the founder cells divide asymmetrically, producing unequally sized daughter cells with distinct fates (Fig. 1d,e ). The smaller daughters give rise to the heart progenitor lineage (trunk ventral cells) whereas their larger sisters give rise to anterior tail muscle precursors. Previous research indicates that heart progenitor induction involves activation of MAP kinase (MAPK) by FGF9/16/20 (also known as FGF9; refs 14,15) . However, previous work did not address how FGF9 differentially induces heart fate in the smaller daughter cells and not in their sister lineage.
We initiated our investigation into differential heart progenitor induction by examining the precise in vivo relationship between the FGF9-expression domain and labelled founder cells ( Fig. 1a-d and Supplementary Fig. S1 ). These assays indicate that founder cells are first exposed to high levels of FGF9 during gastrulation (stage 13) when FGF9 is upregulated in the adjacent mesenchyme and tail muscle lineages ( Fig. 1a versus b and Supplementary Fig. S1a versus b ). At this stage, both founder cells (B8.9 and B8.10) are surrounded by FGF9-expressing cells ( Supplementary Fig. S1b ). This pattern persists as each founder cell divides to produce a smaller anterior-ventral heart progenitor and a larger posterior-dorsal daughter (Fig. 1c-e and Supplementary Fig. S1c,d ). FGF9 antibody staining confirms that FGF9-producing cells are positioned all along the division axis of neighbouring mitotic founder cells ( Supplementary Fig. S1e,f) . Thus, it seems that differential induction does not reflect differential exposure to the inductive ligand.
We validated this interpretation of our FGF9 expression assays through dissociation of transgenic embryos expressing green fluorescent protein under the control of the mesoderm posterior enhancer (Mesp-GFP or Mesp-ensGFP) and red fluorescent protein under the control of the forkhead box F enhancer (FoxF-RFP; Fig. 1f-j and Supplementary Fig. S2 ). In these assays, Mesp-GFP marks L E T T E R S (e) Top, in vivo dpERK antibody staining indicates differential MAPK activation in the smaller heart progenitor cells (arrowheads) shortly after founder cell division; lateral view; scale bar, 10 µm. (a-e) Bottom, illustrations of the spatial relationship between founder cells (B8.9 and 8.10) and FGF9 -expressing cells (hp, heart progenitor; atm, larger sister cell lineage; m, mesenchyme; GPI-GFP refers to a membrane-anchored GFP fusion, glycosylphosphatidylinositol-GFP driven by the Mesp enhancer). (f-i) Representative founder cell clone pairs resulting from staged dissociations; scale bars, 5 µm. (j) Percentage of induction (FoxF-RFP-positive cells) produced by founder cells isolated at discrete stages; n = 1,117 for stage 10-12, n = 658 for stage 13, n = 651 for stage 14 and n = 693 for stage 15. Embryos are shown anterior to the left in these and all subsequent figures. Note that in these and subsequent figures founder cells are labelled by Mesp-ensGFP (a fusion of the microtubule binding protein ensconsin with multiple copies of GFP). See Methods for further details.
the founder cell lineage and FoxF-RFP serves as a read out for FGF/MAPK induction 14 . Although staggered development of founder cells both within and between embryos complicated this data set (Supplementary Figs S1, S2 and Movie S4), the overall trends were clear. Individual founder lineage cells dissociated between stages 10-12 produce FoxF-RFP-negative clone pairs, indicating the absence of prior induction ( Fig. 1f ). At stage 13, levels of induction increased significantly ( Fig. 1g,j) . Strikingly, founder cells isolated at stage 13 undergo uniform induction, generating homogeneous pairs of FoxF-RFPpositive daughters ( Fig. 1g , 97/115 induced pairs). A significant rise in the prevalence of heterogeneous FoxF-RFP expression, indicative of differential induction, occurs in founder cell clones dissociated shortly before asymmetric division (stage 14, Fig. 1h ,i and Supplementary Fig.  S2d ; n = 264, P = 0.004). These results indicate that initial exposure to FGF9 results in uniform receptor occupancy. Furthermore, it seems that an extrinsic cue present only in intact embryos localizes inductive signalling shortly before asymmetric division.
We next examined the morphology of mitotic founder cells. Just before division (stage 14), founder cells exhibit a striking, highly polarized enrichment of protrusions ( Fig. 2a,b and Supplementary  Fig. S3b and Movies S1-S2). This protrusive fringe is concentrated along the anterior-ventral edge of founder cell pairs (asterisks in Fig. 2a,b and Supplementary Movies S1, S2); the region where heart progenitor daughter cells will shortly emerge ( Fig. 2c and Supplementary Movie S3). Remarkably, the founder cell protrusive fringe penetrates the underlying ventral epidermis, sometimes forming an invasive membrane that outlines the basal-lateral surfaces of neighbouring epidermal cells ( Fig. 2b and Supplementary Movie S2). Through time-lapse imaging we observed the formation of large anterior-ventral founder cell protrusions within living embryos (Supplementary Movies S4-S6). Founder cell protrusions are highly invasive, reaching deep into the underlying epidermis (Supplementary Movie S4). These protrusions are transient structures forming just before founder cell division and terminating shortly after division is Fig. 2e ) illustrating the method for comparing pTyr levels between the anterior-ventral (AV) and posterior-ventral (PV) membranes. (h) Quantitative analysis of membrane pTyr ratios (AV versus PV). Note that significant pTyr polarization (asterisk) was first observed at stage 14 (stage 12 P = 0.64, n = 92; stage 13 P = 0.21, n = 89; stage 14 P = 9.3 × 10 −12 , n = 89) and that this polarization was dependent on FGF signalling (stage 14 Mesp-FGFRdn P = 0.103, n = 57). Scale bars, 10 µm.
complete (Supplementary Movies S4-S6). Thus, protrusive activity (stage 14/15) does not correlate temporally with initiation of heart progenitor migration (stage 18). In summary, we have found that the founder cell cortex is highly polarized, generating invasive protrusions at the site of differential induction. The observed correlation between protrusions and localized induction may reflect an instructive role for cortical actin in regional FGF signalling 16, 17 . To explore this hypothesis, we assayed FGF receptor activation using a phospho-tyrosine (pTyr) antibody. We simultaneously visualized filamentous actin (F-actin) in founder cells through targeted expression of the actin-binding fusion protein utrophin-GFP (ref. 18 ; Fig. 2d -f). Regional enrichment of F-actin along the founder cell cortex was consistently associated with regional enrichment of pTyr staining in the adjacent membrane ( Fig. 2d-f ). At stage 13, founder cells exhibit uniform, ventral enrichment of F-actin mirroring un-polarized protrusions along this surface ( Fig. 2d and Supplementary Fig. S3a ). pTyr staining in the adjacent ventral membrane was also un-polarized ( Fig. 2d , quantified in Fig. 2h ). Beginning at stage 14, F-actin and pTyr staining become concentrated at the anterior-ventral edge ( Fig. 2e ,h) mirroring the emergence of the protrusive fringe at this stage ( Fig. 2a and Supplementary  Fig. S3b ). This cytoskeletal/signalling polarity persists after division, with the smaller anterior-ventral heart progenitor daughter cells exhibiting distinctly higher levels of utrophin-GFP and pTyr staining in comparison with their larger posterior-dorsal sisters ( Fig. 2f ). Thus, as founder cells prepare to divide, it seems that cortical F-actin and FGF receptor activation are gradually localized to the presumptive heart progenitor membrane ( Fig. 2g ). We verified that polarized pTyr staining reflects polarized FGF receptor activation through targeted expression of a previously characterized dominant-negative FGF receptor 14 (Mesp-FGFRdn). This manipulation reduced the level of pTyr staining in the founder cells and eliminated anterior-ventral enrichment (Fig. 2h ). The polarization of inductive signalling between stages 13 and 14 correlates with the shift from uniform induction to differential induction observed in founder cells isolated at these stages ( Fig. 1g -i and Supplementary Fig. S2 ). These results indicate that FGF receptor activation is locally enhanced in association with polarized protrusive activity.
Localized activation of the Rho GTPase, CDC42 (orthologue to cell division control 34 protein 42), often directs polarized actin dynamics 19, 20 . We therefore examined CDC42 activation in stage 14 founder cells using a Förster resonance energy transfer (FRET)-based CDC42 activation bioprobe 21 (Fig. 3a,b) . The bioprobe revealed a modest but significant polarization of CDC42 activation along the anterior-ventral-posterior-ventral axis, whereas an inactive control probe showed no polarization (Fig. 3b ). These assays indicate that CDC42 activation is significantly enriched on the anterior-ventral side, the site of enhanced protrusion and subsequent differential induction.
Our correlative data are indicative of a functional role for localized CDC42 activity in induction. To test this hypothesis, we disrupted localized CDC42 activity by expressing constitutively active CDC42 in the heart founder cell lineage 22 (Mesp-Cdc42 Q61L ). Whereas targeted expression of full-length CDC42 had no discernible impact (Figs 3g and 4a,d and Supplementary Fig. S3b ), targeted expression of the GTPase-defective Q61L mutant generated uniform protrusive activity ( Supplementary Fig. S3c ) and uniform ventral pTyr staining ( Fig. 4d ), indicating depolarization of FGF receptor activation. Most significantly, Mesp-Cdc42 Q61L disrupted differential induction (Figs 3d and 4b) .
In most Mesp-Cdc42 Q61L embryos, FoxF reporter ( Fig. 3g ) and heart marker gene expression (FoxF, Hand-like and GATA-a; Supplementary  Fig. S4 ) were expanded and often encompassed all founder lineage cells. Additional experiments demonstrate that Cdc42 Q61L potentiates induction through the FGF/MAPK pathway ( Supplementary Fig. S5 ).
Intriguingly, targeted expression of a different constitutively active CDC42 construct, the fast-cycling mutant F28L (Mesp-Cdc42 F28L ), did not have any discernible impact on founder cell induction ( Fig. 3e,g) . (c-f) Representative results from induction assays, fluorescent reporters and transgenic backgrounds as indicated above and to the left respectively. In c, the red channel in the merged image was amplified to better visualize the embryo. (g,h) Quantitative data showing the percentage of transgenic embryos exhibiting loss of localized induction (n = 375 for Cdc42, n = 466 for Q61L, n = 461 for F28L, n = 240 for F28L Rho and n = 250 for Rho; g) and loss of polarized CDC42-GFP enrichment along the heart progenitor/ventral membrane (n = 31 for Cdc42, n = 31 for Q61L, n = 25 for F28L and n = 30 for F28L Rho; h). (i) Lateral projection of dividing founder cell exhibiting enrichment of CDC42-GFP (green) along the presumptive heart progenitor membrane (asterisk). Scale bars, 10µm, except for c, main panel, 20µm.
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We therefore reasoned that localized CDC42 activity requires sustained association with the anterior-ventral plasma membrane. According to this model, periodic membrane release/inactivation of the fast-cycling mutant would prevent it from generating ectopic CDC42 activity. In contrast, sustained and unlocalized membrane association allows the Q61L mutant to generate uniform CDC42 activity. We tested this hypothesis by mutating the Rho insert domain in the Cdc42 F28L construct (Mesp-Cdc42 F28L Rho ). Previous studies have shown that the Rho insert can facilitate removal of Cdc42 constructs from the membrane and subsequent inactivation in the cytosol 23, 24 . As predicted by our model, targeted expression of the fast-cycling Rho-deletion mutant (Mesp-Cdc42 F28L Rho ) generated significant levels of uniform induction, whereas targeted expression of a wild-type Rho-deletion mutant (Mesp-Cdc42 Rho ) had no effect ( Fig. 3f,g) . These results demonstrate that disruptions of differential induction by activated CDC42 constructs are not merely an artefact of hyperactive CDC42. Instead, our manipulations of CDC42 strongly support a model in which polarized activation of CDC42 at the anterior-ventral membrane promotes regional enrichment of inductive signalling.
We next examined CDC42 localization through targeted expression of Cdc42-GFP fusion proteins (Mesp-Cdc42-GFP, Mesp-Cdc42 Q61L -GFP, Mesp-Cdc42 F28L -GFP and Mesp-Cdc42 F28L Rho -GFP; Fig. 3h ,i and Supplementary Fig. S3f,g) . By co-staining with anti-tubulin antibodies, we were able to visualize CDC42 localization during discrete cell cycle phases and precisely identify the presumptive heart progenitor membrane in mitotic founder cells. Cdc42-GFP and Cdc42 F28L -GFP were strongly enriched along the presumptive heart progenitor membranes of dividing founder cell pairs (Fig. 3h ,i and Supplementary Fig. S3f ). In contrast, Cdc42 Q61L -GFP and Cdc42 F28L Rho -GFP were expressed in a more diffuse, uniform pattern ( Fig. 3h and Supplementary Fig. S3g ). Thus, as predicted by our model, it seems that disruption of polarized CDC42 activation along the founder cell membrane is required to disrupt regional signalling (compare Fig. 3g with h). Taken together with our data on localized protrusions ( Fig. 2) , these results indicate that polarized CDC42 may impact regional induction through regulation of cytoskeletal dynamics.
We next focused on determining whether localized actin dynamics mediate the impact of polarized CDC42 on inductive signalling ( Fig. 4 and Supplementary Fig. S6 ). To generate protrusions, CDC42 often works in tandem with Rac to activate the actin nucleator Arp2/3 (actinrelated protein 2/3; ref. 25) . We therefore anticipated that expression of constitutively active Rac would disrupt differential induction. As predicted, targeted expression of active Rac (Mesp-Rac G12V ; refs 26, 27) potentiated uniform induction (P = 2.5 × 10 −3 , Supplementary  Fig. S6c ). We also anticipated that interference with Arp2/3 function would disrupt differential induction. We therefore treated embryos with the Arp2/3 inhibitor Ck-666 (ref. 28 ) during the period of founder cell polarization (stages [12] [13] [14] . As predicted, this treatment disrupted localized enhancement of founder cell pTyr staining and potentiated uniform induction (P = 9.8 × 10 −3 , Supplementary Fig. S6a-d) . However, whole-embryo disruption of actin nucleation is likely to have numerous indirect effects on development that may impact induction. We therefore attempted to specifically interfere with CDC42-mediated actin nucleation in the founder cell lineage. Wasp (Wiskott-Aldrich syndrome protein) functions downstream of CDC42 to promote Arp2/3-mediated nucleation of actin in filopodia and invadopodia 19, 20 . We constructed a truncated form of is thought to generate inactive-complex formation and previous studies have demonstrated that Wasp VCA specifically disrupts CDC42mediated activation of endogenous Wasp 29, 30 . Targeted expression of Wasp VCA (Mesp-Wasp VCA ) seemed to reduce but not fully disrupt the polarity of founder cell protrusions ( Supplementary  Fig. S3e ). Accordingly, this manipulation reduced but did not eliminate polarized pTyr staining ( Fig. 4d ) and had no significant impact on differential induction (P > 0.5). We then co-transfected embryos with Mesp-Wasp VCA and Mesp-Cdc42 Q61L . In these embryos, disruption of the Wasp-CDC42 interaction rescues the localization of founder cell protrusions (compare Supplementary Fig. S3c versus d) and restores polarized tyrosine phosphorylation (Fig. 4d ). Remarkably, co-transfection with Wasp VCA also led to a significant restoration of differential induction in the Cdc42 Q61L transgenic background (Fig. 4c,e ). These experiments strongly support a model in which localized protrusions translate polarized CDC42 activity into regional induction (Fig. 4f ). However, the Wasp VCA construct may act indirectly to inhibit the association of active CDC42 with other effectors. To alleviate this concern we co-transfected embryos with constructs predicted to bind CDC42 without disrupting downstream actin nucleation (full-length Wasp and the CDC42-binding domain of partitioning-defective protein 6, Par6-CRIB). Targeted expression of these control constructs (Mesp-Wasp and Mesp-Par6-CRIB) failed to restore differential induction in the Mesp-Cdc42 Q61L background (Fig. 4e ). This study illustrates how polarized actin dynamics can potentiate localized receptor tyrosine kinase (RTK)/MAPK signalling in the context of uniform receptor occupancy (Fig. 4f) . Previously, the cytoskeleton has been shown to modulate RTK/MAPK signalling during yeast mating, immune synapse formation, oncogenesis, cell migration and in vitro cell fate decisions 2, 4, 17, 31, 32 . Our results indicate that the cytoskeleton also modulates growth factor signalling during in vivo specification of embryonic cell types, including the heart lineage.
Our findings in Ciona may reflect a conserved role for cytoskeletal dynamics in vertebrate cardiomyocyte specification. Although FGF signalling helps to establish vertebrate cardiomyocyte identity 8 , previous studies have not addressed the potential influence of intrinsic mechanical/cytoskeletal properties on cardiomyocyte induction. There are, however, stem cell data implicating cell-matrix interactions in cardiomyocyte differentiation 33 , raising the intriguing possibility that matrix-mediated integrin signalling underlies polarization of vertebrate cardiac progenitor cells. Integrin signalling can modulate GTPases and RTK signalling 34 and is closely tied to the formation of invasive membranes 35 . Thus, it will be of great interest to examine whether mechanoregulatory interactions between matrix, integrin and cytoskeleton regulate heart fate in Ciona and vertebrate embryos.
This report has critical implications regarding the function of invasive protrusions. Generally, large invasive membranes help anchor cells to neighbouring tissues or permit migration through the surrounding matrix 35, 36 . However, dividing Ciona founder cells are not engaged in either of these processes. This raises the possibility that invasive membranes can function primarily as signalling regulators; acting like antennae primed for localized signal transduction. This represents a new perspective on invasive membranes and how they may contribute to a variety of signal-mediated processes, ranging from cancer metastasis to developmental patterning.
METHODS

Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology
Note: Supplementary Information is available on the Nature Cell Biology website DOI: 10.1038/ncb2291 METHODS All data shown represent at least three independent trials (n values are shown in the main text) with the following exceptions: in situ hybridizations ( Supplementary  Fig. S1 ) are each based on one trial and the FRET data in Fig. 3 are based on two independent trials. Constructs to disrupt ephrin signalling 38 The Mesp-Cdc42 mutations were made using site-directed mutagenesis of the Mesp-Cdc42 plasmid described above with the following primer sequences. The products were then inserted back into the MespHA or Mesp-GFP fusion vectors and confirmed by sequencing. Cdc42 Rho , 5 -GTACACAAGTTGATTTAAGGAAACAAAAAGCAATTACTCA-3 ; Cdc42 F28L 5 -TACACAACTAATAAGTTACCTCAAGAGTATGTCCCG-3 .
In situ hybridizations. Fluorescent in situ hybridizations were carried out as previously described 45 . For more details see http://www.mcrp.med.arizona.edu/ html/braddavidson/links.html. Anti-sense RNA probes for GATA-a and FGF9 were created from Gene Collection 1 clones, GC02d03 and GC29b12, respectively. Anti-sense RNA probes for FoxF, Nkx and Hand-like were previously described 45, 46 .
Antibody staining. For visualization of transgenically labelled founder cells, embryos were either fixed as previously described for in situ hybridizations 45 and then stained with antibodies, or embryos were fixed in 0.4% formaldehyde overnight at 4 • C and mounted for direct visualization of fluorescence signal. For FGF9 and α-tubulin, embryos were fixed in cold methanol for 1-2 h, rinsed in phosphatebuffered Tris and stained with either rabbit anti-α-tubulin (1:500 in PBS with BSA, Sigma T3526) or our custom rabbit-anti-FGF9_270 (1:200 in PBS/BSA, see below). Founder cells were labelled with a number of GFP reporter constructs. Mesp-GPI (glycosyl phosphatidylinositol)-GFP refers to a membrane-anchored GFP coding region subcloned downstream of the Mesp enhancer from the sna > GPI-GFP vector 47 . Mesp-ens-GFP refers to an ensconsin-3×GFP coding region subcloned downstream of Mesp 48 . Antibody staining with pTyr (Millipore 05-1050, 1:100) and dpERK (double-phosphorylated extracellular signal-regulated kinase; Sigma M8159, 1:50) was carried out as previously described for dpERK (ref. 14); for more details see http://www.mcrp.med.arizona.edu/html/braddavidson/links.html. For measurements of anterior-ventral/posterior-ventral staining ratios, a ventral optical slice was used with the focus set to the widest section of the cell. Five equidistant lines were drawn from the anterior to the posterior across the central region of each cell and measurements of maximal pTyr staining intensity were taken at each side of the cell along these lines. The values for each side were averaged. A ratio of these averaged values was used to estimate the staining differences between anterior-ventral and posterior-ventral membranes. For characterization of CDC42-GFP localization, embryos were fixed in cold methanol (see above) during the time of founder cell mitosis (6:50-7:00 hours post-fertizilation, hpf) and stained with antibodies against α-tubulin (Sigma T6199) and GFP (see above) along with appropriate secondaries (see above). Transgenic founder cell pairs were imaged to create high-resolution confocal z stacks (1.0 µm section). Three-dimensional projections of stained CDC42-GFP founder cell pairs were assigned random labels and scored blind into two categories: robust ventral enrichment in both cells, or diffuse unlocalized staining in one or both cells. Dissociation assay. Dissociation was carried out as previously described 43 with the following exceptions. Transgenic Mesp-GFP and Mesp-FoxF embryos were reared at 18 • C to the appropriate stage (stage 10-15), at which point they were mechanically dissociated in Ca/Mg-free sea water (CMF) +0.1% BSA for approximately 1 min. After every wash, each sample was centrifuged for 120 s at 1,000g and re-suspended in CMF + 0.1% BSA. Samples were then washed through a 12 × 75 cell-strainer cap (BD Falcon #353335) and into a 10 ml dish containing filtered artificial sea water and 0.1% BSA. Cells were then returned to the incubator until the intact control embryos reached stage 23. Cells were then fixed in 0.4% formaldehyde overnight at 4 • C. Whole embryos were fixed concurrently to ensure proper staging.
FRET. Use of the FRET probes was conducted under a transfer agreement with M. Matsuda (Osaka University, Japan). For the Cdc42 (Raichu-CDC42) and Cdc42 (N17) FRET probes 49 , N-and C-terminal fragments (YFP:Pak1:Cdc42 and CFP respectively) were cloned in tandem downstream of Mesp, using PCR-generated Not1 and BamH1 sites for the N-terminal fragment and a PCR-generated BamH1 and endogenous EcoR1 site for the C-terminal fragment, into the Mesp-Cdc42-GFP vector described above. Samples were fixed as for in situ hybridizations and mounted in glycerol. Imaging was carried out with a Zeiss LSM 510 laser scanning confocal microscope using a ×40 Plan-Apochromat objective lens. Acceptor photobleaching FRET analysis was carried out according to established protocols 50 with the following exceptions. A 458 nm excitation laser was passed through a 458/514 dichroic beam splitter with laser power set at 10%. Fluorescent emission was passed through a 480-520 nm band-pass filter for cyan fluorescent protein (CFP) and a 535-590 band-pass filter for yellow fluorescent protein (YFP). Photobleaching was carried out with a 458 nm laser at 100% transmission for 1,000 iterations. Focus was set to a ventral slice selected by finding the widest section of the cell pairs. Then the entire slice within the B7.5 cells was bleached and regions of interest of equal size were placed, by hand, at the centre of each cell on the anterior and posterior side of the ventral slice.
Statistical analysis. In all graphs, error bars represent confidence intervals set at 95% (α = 0.05) as calculated using Microsoft Excel. Significance was determined using Student's t -tests with two-tailed distributions also using Microsoft Excel. Weighted averages were used for the dissociated pairs data (S2) and these averages were also used for the Student's t -tests of those data.
Live-cell imaging. Ciona embryos were electroporated with 95 µg of Mesp-ensconsin-3×GFP and grown until 5.5 hpf (∼stage 12) at 18 • C. Imaging was carried out with a Zeiss LSM5 Exciter inverted laser scanning confocal microscope. Embryos were imaged in a Nunc Lab-Tek Chambered #1.0 Borosilicate cover glass (Sigma) using a ×63 C-Apochromat 1.2 W objective with a 0.8 zoom. The embryos were cooled to 16 • C and z stacks of the embryos were acquired every 4 min (Supplementary Movie S1) and every 1 min 37 sec (Supplementary Movies S2 and S3). Movies were created by compiling the z stacks in Imaris 6.4.2 (Bitplane) and ImageJ.
FGF9 antibody production.
A 270-base-pair fragment of FGF9 was cloned into pGEX 5 × 1 using the following primers: 5 -AAGAGAATCATGTCAAGAACCGA-AGCAGCAA-3 and 5 -AAGAGCGGCCGCGTCGTAGGCAGACATACCGGTG-3 . This corresponds to the protein sequence 5 -MSRTEAAKVQSVFSAKLGRARR KNSLSVDSSTPQKLTEETMPVVHDRLPDLSLWSKIDEELKEQEKSSANGLLSS TSARSKRNTGMSAYD-3 .
Isolation of glutathione S-transferase (GST)-tagged FGF9_270 protein from transformed BL21 competent cells involved standard protocols (see link below for more information). Elution fractions were stored at −80 • C until sufficient protein was collected for antibody production. Purified GST-FGF9_270 protein was sent to ProteinTech Group Inc. for rabbit polyclonal antibody production. The antibody was then purified using a maltose-binding protein (MBP)-FGF9_270 fusion protein and concentrated using Millipore Ultrafree 10 K concentrators. The concentration DOI: 10.1038/ncb2291
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of the FGF9 antibody was determined (1.5 mg ml −1 ) using the Bradford assay. A more detailed protocol can be found at http://www.mcrp.med.arizona.edu/html/ braddavidson/links.html.
Verification of antibody specificity. The specific binding of rabbit anti-FGF9_270 to Ciona FGF9 protein was validated using western hybridization assays according to standard protocols. For more details see http://www.mcrp.med. arizona.edu/html/braddavidson/links.html.
Drug treatments. Treatment of Ciona embryos with U0126 was carried out as previously described 14 . For Arp2/3 inhibitor studies, 100 mM frozen dimethylsulphoxide stock solutions of Ck-666 or Ck-689 (EMD #182515 and #182517) were diluted at 1:1,000 in filtered sea water immediately before treatment. Stage 12 transgenic embryos (5.5 hpf) were then added simultaneously to the treatment solutions, incubated for ∼1 h (stage 14-15) and transferred simultaneously through two rinses in 10 ml of filtered sea water; they were then incubated to stage 21 or 22, fixed and mounted for analysis of induction. Both founder cells divide to produce the smaller heart progenitor cell at the anterior/ventral/lateral side but B8.9 tends to divide with a more anterior/ ventral orientation while B8.10 tends to divide with a more ventral/lateral orientation. For simplicity we designate the side of the founder cell that produces the heart progenitor as anterior/ventral. For optical sections (Fig. 2) we sliced founder cells along this elongated, orthogonal axis. (d'-d''') Lateral to medial sections. FGF9 is expressed anterior to one pair of newly divided founder lineage cells (d'-d'') and just lateral to the second pair (d''d'''). (ef') Mesp-Esc3XGFP labeled founder lineage cells were visualized with an anti-GFP antibody (red) and FGF9 protein expression was visualized with the anti-FGF9_270 antibody (green). (e-f) Lateral and (f') ventral projections of confocal stacks, anterior tail muscle progenitors indicated by arrowheads and heart progenitors by asterisks. As the founder cells divide during stages 14-15, FGF9 protein is detected in all FGF9 expressing tissues (dorsal epidermis, mesenchyme, tail muscle and the founder cells themselves). These assays suggest that exposure to FGF9 is uniform along the plane of founder cell division. In particular, there is no evidence for a ventral bias in FGF9 signal associated with the clear ventral bias in FGF9 mediated induction, as emphasized in (e' and e''), magnified and schematic views of (e). Because of staggered development, numerous founder cells isolated at this stage formed singlets, indicating that division had already occurred or that the cells had separated during handling. There appears to be a short window during which induction is heterogeneous prior to founder cell division and this may explain why no more than ~20% of isolated founder lineage cells display this phenotype.
Figure S6
Manipulations of cytosekeletal regulators disrupt differential induction while manipulations of Ephrin and Cool1 do not affect differential induction. (a-b) Representative stage 21 embryos treated with the inactive enantiomer Ck-689 (a) or the ARP2/3 inhibitor Ck-666 (b) prior to founder cell division. (c) Quantitation of expanded induction in control (Ck-689, n=232) vs. experimental (Ck-666, n=193) and in control embryos (lacZ, n=298) vs. embryos with targeted expression of constitutively active Rac (Mesp-Rac G12V, n=242). Targeted expression of wild-type Rac (Mesp-Rac) also had no discernable impact on differential induction (% expanded induction = 11.5, st. dev. 3.2, 3 trials, n=135). We also tested the effect of targeted constitutively active RhoA (Mesp-RhoA-Q61L, n=48, two trials). This manipulation led to a severe disruption in founder cell cytokinesis, precluding analysis of fate specification. (d) Quantification of phospho-tyrosine ratios (as described for Fig. 2h ) for Ck-689 and Ck-666 treated embryos (n=48 for each column). Previous studies have indicated that Ephrin signaling can differentially inhibit MapK signaling in the Ciona notochord/neural mother cell 38 . We therefore expressed dominant negative Eph5 or Eph3 receptors in the founder cell lineage (cloned downstream of Mesp from VES89_N23 and GC16p22 respectively using the following primers; Eph5DNf-aaagcggccgcCTGGAAAATGGAAAG GTTTG; Eph5DNr-tttGCTCAGCCACTATATTCGATCTCGGGGTGG; Eph3DNf-aaagcggccgcTCAGCACTTTTAAAGGatg; Eph3DNr-tttgctcagcgtttgatcaat ctAggttgcg). These manipulations had no discernible effect on founder cell induction (data not shown). We also tested the possibility that Cool-1 mediated regulation of FGFR ubiquitination might mediate the effect of activated CDC42 on differential induction 39 . However, targeted expression of a dominant inactive form of Cool-1 (W43K, cloned from GC07a01 using the following primers; Cool1F-aaaGCGGCCGCCAGAATGGGTGAATA CGTTTTGCC; Cool1R-aaaGAATTCgctagcactctggtgaag; and mutated using CATCAAAGACAGAAGGTGGAaaGTGGGAGG and its reverse complement) had no discernable impact on induction when co-transfected with Cdc42 Q61L or in control embryos (data not shown). Scale bars are 20 mm.
